Request Sample Form


Phone No.*:


Service Intersted In:

Download Complete Report

Your Name*:


Contact Number*:


Service Interested In* (required)

Your Requirment*:

AZ confirms cardiovascular safety with roxadustat results

AstraZeneca has announced top-line results from the pooled cardiovascular (CV) safety analyses of its global Phase III roxadustat programme.

May 16th, 2019|News|

AZ announces Phase I DS-8201 results

AstraZeneca has announced two Lancet Oncologypublications of its Phase I dose-expansion results of DS-8201 (trastuzumab deruxtecan) in HER2-positive metastatic breast and gastric cancer.

May 2nd, 2019|News|

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada.

September 25th, 2018|News|